Literature DB >> 8445487

Proliferation and differentiation of tumour cells from B-cell lymphoma of mucosa-associated lymphoid tissue in vitro.

T Hussell1, P G Isaacson, J Spencer.   

Abstract

Several characteristics of lymphomas of mucosa-associated lymphoid tissue (MALT type) suggest that they are antigen-dependent and that their growth parodies a normal immune response. We have previously shown that three cases of low-grade B-cell MALT-type lymphoma recognize autoantigens. In this study, we investigated the response of three low-grade and one high-grade case of MALT-type lymphoma to anti-idiotypic antibody as a model of antigen binding either alone or as a co-stimulus with B-cell mitogens. We also studied the response of tumour cells to interleukin-6 (IL-6), which induces differentiation to immunoglobulin-producing cells in many systems. Of the four cases studied, one low-grade case showed markedly enhanced proliferation in response to anti-idiotype alone. This could not be increased by the addition of mitogens. In the remaining two low-grade cases, mitogen responsiveness was observed which was affected by anti-idiotype either by an enhancement or by a reduction in the proliferative response. The high-grade case failed to respond to the stimuli studied. No response to IL-6 was observed. This study supports the suggestion that antigen may affect the pathogenesis of low-grade tumours of MALT type.

Entities:  

Mesh:

Substances:

Year:  1993        PMID: 8445487     DOI: 10.1002/path.1711690208

Source DB:  PubMed          Journal:  J Pathol        ISSN: 0022-3417            Impact factor:   7.996


  10 in total

1.  Aggressive mucosa associated lymphoid tissue lymphomas are associated with mutations in Bcl10.

Authors:  J Spencer
Journal:  Gut       Date:  1999-06       Impact factor: 23.059

2.  BCL10 expression in normal and neoplastic lymphoid tissue. Nuclear localization in MALT lymphoma.

Authors:  H Ye; A Dogan; L Karran; T G Willis; L Chen; I Wlodarska; M J Dyer; P G Isaacson; M Q Du
Journal:  Am J Pathol       Date:  2000-10       Impact factor: 4.307

3.  Low-grade B cell lymphomas of mucosa-associated lymphoid tissue (MALT-type) require CD40-mediated signaling and Th2-type cytokines for in vitro growth and differentiation.

Authors:  A Greiner; C Knörr; Y Qin; W Sebald; A Schimpl; J Banchereau; H K Müller-Hermelink
Journal:  Am J Pathol       Date:  1997-05       Impact factor: 4.307

Review 4.  The role of viral and bacterial pathogens in gastrointestinal cancer.

Authors:  Michael Selgrad; Peter Malfertheiner; Lucia Fini; Ajay Goel; C Richard Boland; Luigi Ricciardiello
Journal:  J Cell Physiol       Date:  2008-08       Impact factor: 6.384

5.  Analysis of TH1 and TH2 cytokine production in low grade B cell gastric MALT-type lymphomas stimulated in vitro with Helicobacter pylori.

Authors:  A C Hauer; T M Finn; T T MacDonald; J Spencer; P G Isaacson
Journal:  J Clin Pathol       Date:  1997-11       Impact factor: 3.411

Review 6.  Mucosa-associated lymphoid tissue (MALT) lymphoma: a practical guide for pathologists.

Authors:  Chris M Bacon; Ming-Qing Du; Ahmet Dogan
Journal:  J Clin Pathol       Date:  2006-09-01       Impact factor: 3.411

7.  Characterization of tumor-infiltrating T lymphocytes in B-cell lymphomas of mucosa-associated lymphoid tissue.

Authors:  A Koulis; T Diss; P G Isaacson; A Dogan
Journal:  Am J Pathol       Date:  1997-11       Impact factor: 4.307

8.  Infrequent BCL10 mutations in B-cell non-Hodgkin's lymphomas.

Authors:  H Takahashi; Y Hosokawa; R Suzuki; Y Morishima; S Nakamura; M Seto
Journal:  Jpn J Cancer Res       Date:  1999-12

Review 9.  Recent Advances in the Genetic of MALT Lymphomas.

Authors:  Juan José Rodríguez-Sevilla; Antonio Salar
Journal:  Cancers (Basel)       Date:  2021-12-30       Impact factor: 6.639

10.  CCR6 activation links innate immune responses to mucosa-associated lymphoid tissue lymphoma development.

Authors:  Boguslawa Korona; Dagmara Korona; Wanfeng Zhao; Andrew C Wotherspoon; Ming-Qing Du
Journal:  Haematologica       Date:  2022-06-01       Impact factor: 11.047

  10 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.